Safety and Efficacy of AMG 827 in Subjects With RA
Status:
Terminated
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
This is an extension study for subjects who participated in Protocol 20090061 (NCT00950989).
All subjects in this study will receive a 210mg injection of AMG827 for treatment for their
Rheumatoid Arthritis for up to 5 years.